1. Home
  2. APH vs VRTX Comparison

APH vs VRTX Comparison

Compare APH & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APH
  • VRTX
  • Stock Information
  • Founded
  • APH 1932
  • VRTX 1989
  • Country
  • APH United States
  • VRTX United States
  • Employees
  • APH N/A
  • VRTX N/A
  • Industry
  • APH Electrical Products
  • VRTX EDP Services
  • Sector
  • APH Technology
  • VRTX Technology
  • Exchange
  • APH Nasdaq
  • VRTX Nasdaq
  • Market Cap
  • APH 113.0B
  • VRTX 101.2B
  • IPO Year
  • APH 1991
  • VRTX 1991
  • Fundamental
  • Price
  • APH $119.05
  • VRTX $391.36
  • Analyst Decision
  • APH Buy
  • VRTX Buy
  • Analyst Count
  • APH 10
  • VRTX 25
  • Target Price
  • APH $108.80
  • VRTX $495.77
  • AVG Volume (30 Days)
  • APH 8.2M
  • VRTX 1.4M
  • Earning Date
  • APH 10-22-2025
  • VRTX 11-03-2025
  • Dividend Yield
  • APH 0.55%
  • VRTX N/A
  • EPS Growth
  • APH 50.29
  • VRTX N/A
  • EPS
  • APH 2.51
  • VRTX 14.07
  • Revenue
  • APH $18,818,000,000.00
  • VRTX $11,418,800,000.00
  • Revenue This Year
  • APH $45.19
  • VRTX $10.93
  • Revenue Next Year
  • APH $10.73
  • VRTX $9.54
  • P/E Ratio
  • APH $47.45
  • VRTX $27.72
  • Revenue Growth
  • APH 40.51
  • VRTX 10.46
  • 52 Week Low
  • APH $56.45
  • VRTX $362.50
  • 52 Week High
  • APH $120.80
  • VRTX $519.88
  • Technical
  • Relative Strength Index (RSI)
  • APH 69.21
  • VRTX 42.84
  • Support Level
  • APH $117.82
  • VRTX $387.19
  • Resistance Level
  • APH $120.51
  • VRTX $398.29
  • Average True Range (ATR)
  • APH 2.84
  • VRTX 7.04
  • MACD
  • APH 0.63
  • VRTX 1.89
  • Stochastic Oscillator
  • APH 88.60
  • VRTX 32.06

About APH Amphenol Corporation

Amphenol is a global supplier of connectors, sensors, and interconnect systems. Amphenol holds the second-largest connector market share globally and sells into the end markets of automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks. Amphenol is diversified geographically, with operations in 40 countries.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: